GPCR

Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule therapeutics for metabolic and cardiopulmonary diseases. Headquartered in South San Francisco, California, the company leverages its structure-based drug discovery platform to design targeted therapies that address significant unmet medical needs. The company's lead product candidate, GSBR-1290, is an oral small molecule GLP-1 receptor agonist being developed for the treatment of obesity and type 2 diabetes, representing a potentially differentiated approach to competing with injectable GLP-1 therapies. Structure Therapeutics also advances other pipeline candidates including amylin receptor agonists and oral PDE4 inhibitors for pulmonary arterial hypertension. The company completed its initial public offering in February 2023, raising capital to advance its clinical programs. In 2024, Structure Therapeutics reported positive Phase 1b data for GSBR-1290 demonstrating meaningful weight loss and favorable tolerability, positioning the asset for Phase 2 development. The company maintains strategic partnerships and collaborations to expand its pipeline and platform capabilities. With a focus on oral bioavailability and drug-like properties, Structure Therapeutics aims to overcome traditional limitations of peptide-based therapies in the large and growing metabolic disease market.